Details:
Interim results from ten evaluable patients after completion of intensive DSR 1.0 (alfapump DSR Therapy) period demonstrated that DSR therapy safely, effectively and rapidly eliminated persistent congestion and restored euvolemia, resulting in mean weight loss of 6kg.
Lead Product(s): Alfapump DSR Therapy,Dapagliflozin
Therapeutic Area: Cardiology/Vascular Diseases Product Name: DSR 1.0
Highest Development Status: Phase II Product Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable July 19, 2022